Economy · News reference
Gold Gains 1%; Performance Food Group Shares Fall After Q4 Results
Dow Jones up 0.1%, NASDAQ up 0.47%, S&P 500 up 0.24%. Tech stocks up 1.1%, communication services down 1.3%. Performance Food Group shares down 6% after reporting earnings miss. AII up 17%, EROC up 20%, BOXL up 69%. NCMI down 31%, UAMY down 22%, STRO down 16%. Oil down 0.1%, gold up 1.1%. Eurozone mixed, Asian markets close mixed. CPI rises 3.4% year-over-year in July.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Analysts Adjust Price Targets for Performance Food Group
UBS and Deutsche Bank have updated their price targets for Performance Food Group following the company's recent quarterly earnings report.
Bernstein Maintains Outperform on Performance Food Group, Raises Price Target to $135
Faster Permitting Paths Put Gold-Antimony Projects on Both Sides of the Pacific in Focus
With China's antimony export suspension set to expire in November 2026 and global antimony prices elevated, governments in New Zealand and the United States are accelerating approvals for gold-antimony projects. RUA GOLD submitted its substantive application for the Auld Creek project in New Zealand under the Fast-track Approvals Act, targeting mid-2027 approvals. Nova Minerals received final permits for its Alaska antimony project with $43.4 million in Department of War funding, targeting 2027 production. United States Antimony Corporation began mining operations at Nolan Creek, while Perpetua Resources secured $40 million in additional U.S. Army funding for tungsten evaluation at Stibnite. Alkane Resources reported strong Q1 FY27 production of 39,823 ounces of gold and 396 tonnes of antimony.
Sutro Biopharma Announces Participation in Upcoming Investor Conferences
Sutro Biopharma, Inc. announced that its management team will participate in several investor conferences scheduled for November and December 2026.
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced that management will participate in multiple investor conferences from November through December 2026, including events hosted by Stifel, Truist Securities, UBS, Jefferies, and Piper Sandler. Live webcasts and archived replays will be available on the company's investor relations website.